-

Company Profile for bioAffinity Technologies, Inc.

--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology are conducted in bioAffinity Technologies’ laboratories at the University of Texas San Antonio (UTSA). The Company’s platform technology is being developed to diagnose, monitor and treat many cancers.

Company:

bioAffinity Technologies, Inc.

 

 

Headquarters Address:

22211 W I-10, Suite 1206

 

San Antonio, TX 78257

 

 

Main Telephone:

5054009747

 

 

Website:

www.bioaffinitytech.com

 

 

Type of Organization:

Private

 

 

Industry:

Biotechnology

 

 

Key Executives:

CEO: Maria Zannes

 

 

Public Relations

 

Contact:

Julie Anne Overton

Phone:

5055770918

Email:

jaoverton@mac.com

 

bioAffinity Technologies, Inc.

NASDAQ:BIAF
Details
Headquarters: San Antonio, TX
CEO: Maria Zannes
Employees: 52
Organization: PUB

Release Versions

More News From bioAffinity Technologies, Inc.

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies reports financial results for FY 2025, including record revenue and unit sales for the CyPath Lung test for lung cancer....

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies launches 2,000-patient longitudinal study for its CyPath Lung noninvasive diagnostic for lung cancer....

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies presents research at AAAAI related to identifying drug antibody receptors in sputum for two leading asthma therapies...
Back to Newsroom